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Abstract 
Background: Lyme borreliosis (LB) is the most common zoonotic disease transmitted by ticks 
in the USA and Europe. This review aims to estimate the regional burden of LB in Western 
Europe. Data from previous publications were used to calculate the mean incidence. The mean 
incidence rates were then combined to estimate the regional burden and a population-weighted 
regional burden of disease based on the standardized incidence from the included studies and the 
total population at risk. 
Methods: Reviews and surveillance reports identified by the initial database search were first 
assessed for eligibility by their title and abstract, and subsequently by a more detailed review of 
the source for the most recent data regarding LB. 11 sources of incidence data were included in 
the review, representing 17 countries in total. Incidence estimates were calculated from reported 
values and population data. 
Results: Countries in Western Europe have a large variance in the incidence rates. The highest 
reported incidences for LB were reported in southern Sweden with 464 per 100 000 and the 
lowest in Italy of 0.001 per 100 000. The unweighted mean for the included data provided an 
incidence of 56.3 per 100 000 persons per year, equating to approximately 232 125 cases in one 
year throughout the region. The calculated population-weighted average incidence for the 
regional burden of LB in Western Europe was 22.05 cases per 100 000 person-years. 
Conclusions: LB is an emerging disease and the most common zoonotic infection in Western 
Europe approaching endemic proportions in many European countries. The population-
weighted incidence has been estimated by this study to be 22.04 per 100 000 person-years. 
Concordant and well-conducted surveillance and disease awareness should continue to be 
encouraged to monitor LB as tick numbers and activity increases. 
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An Estimate of Lyme 
Borreliosis Incidence in 
Western Europe 
Background 
Lyme borreliosis (LB), or Lyme disease, is 
the most common zoonotic disease 
transmitted by ticks in the USA and 
Europe.1 The complex of Borrelia bacteria 
that causes Lyme borreliosis is known as 
Borrelia burgdorferi sensu lato. 5 of these are 
known human pathogens (B. afzelii, B. garinii, 
B. burgdorferi sensu stricto, B. baverensis, and 
B. spielmanii) and 3 are suspected human 
pathogens (B. valaisiana, B. bissettii, and B. 
lusitaniae).2,3 This bacterium is transmitted to 
humans and other vertebrates during the 
blood feeding of Ixodid ticks, of which the 
most common in Europe is the Ixodes ricinus, 
or sheep tick.4,5 Early stages of LB will 
commonly present with erythema migrans, a 
skin lesion or rash that can occur between 2 
and 30 days after being bitten by an infected 
tick, which can be successfully treated with 
antibiotics.6 However, if the infection is not 
treated at this early stage, the bacteria will 
disseminate and the localized infection will 
progress into a systemic disease affecting the 
joints, nervous system and, less frequently, 
the heart.7 
Those at highest risk are people residing or 
working in endemic areas of LB, such as in 
forested areas, and have occupations such as 
forestry workers, gamekeepers, farmers, 
military personnel, and rangers.8 
Orienteering, hunting, picnicking, and 
gardening also expose individuals to more 
ticks and therefore increase the risk of 
infection.9 There is also a distinct degree of 
seasonality associated with the risks of LB 
that coincides with the seasonal pattern of 
tick activity. Activity is higher in the warmer 
parts of the year; however, there is a slight 
lag between tick activity and case reporting 
due to the period between infection and 
symptom presentation (2–30 days).10 
The incidence of LB has been increasing 
across the globe, with the number of 
reported cases in Europe rising since the 
early 1990s and expanding in geographic 
distribution.11 These rises in LB have been 
linked to improved diagnostics and 
awareness, increased tick density, increased 
burden of tick disease, and changes in 
climate in recent decades that have allowed 
ticks to spread into higher latitudes and 
altitudes.12,13 There are an estimated 85 000 
cases of LB in Europe each year; however, 
the reporting in Europe is inconsistent and, 
as such, many infections go undiagnosed.10 
Overdiagnosis of LB is also an important 
factor and it is estimated that, in some 
settings, less than a quarter of those referred 
with LB have confirmed LB.14,15 Serological 
testing as part of surveillance reporting 
within several sources may help to address 
this factor, although this in itself is not 
confirmation of LB. However, due to 
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differing collection methods in the included 
sources, overdiagnosis as well as 
underdiagnosis should still be considered 
when analysing these data. Although 
surveillance is increasing for LB, a global 
estimate of disease burden and incidence 
does not exist at the moment, with previous 
reports of incidence in Europe only 
including an overview of selected 
countries.10,16 Differences in the methods of 
case reporting also lead to a more 
problematic estimation of a regional burden 
of disease. While some countries continually 
report LB diagnoses, there is a great 
disparity between countries concerning 
surveillance of all or only some of the early 
and/or disseminated LB cases. An example 
of this is erythema migrans which, while 
present in a large proportion of LB (70–
80%), does not occur in all cases and may 
have led to an under-reporting of the true 
burden of disease.5,17 For a disease of such 
increasing importance and which is likely to 
affect more and more people, it is important 
for policy makers and health providers to 
understand the current burden in their 
region, especially considering that LB and 
chronic LB have been highly controversial 
subjects in politics and the media in recent 
years.18,19 The term chronic LB is often used 
inappropriately. The definition of chronic 
LB is an untreated LB that has developed 
over a long period of time into late-stage 
disseminated LB or into acrodermatitis 
chronica atrophicans (ACA), also known as 
“Herxheimer disease”. Referral to a 
condition of “chronic LB” may in many 
instances actually be a reference to a “post-
Lyme syndrome”, where symptoms have 
persisted despite treatment with antibiotics 
and resolution of the infection.20-24 
This review aims to estimate the regional 
burden of LB in Western Europe. Data 
extracted from included papers were 
standardized in order to calculate the mean 
incidence per 100 000 people per year.  
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The mean incidence rates were then 
combined in order to achieve an estimate of 
the regional burden and a population-
weighted regional burden of disease based 
on the standardized incidence from the 
included studies and the total population at 
risk. 
Methods 
Search strategy 
Articles of importance and relevance were 
identified by an electronic search of 
MEDLINE, Embase, and Global Health 
databases through the Ovid Gateway. These 
were searched with no restriction on 
language for data, from the inception of 
each database up until the beginning of 
March 2013. A search strategy is supplied in 
Box 1, which consists of synonymous terms 
for LB, countries of Western Europe, and 
epidemiological terms of interest. A list of 
the countries searched for is included as part 
of Table 2. Boolean operators were 
employed to link these terms and exclude 
countries that had returned results as part of 
the search but are not defined by the World 
Bank as being in Western Europe (Poland, 
Slovakia, Russia, and Croatia). The only 
exception to this criterion is the Republic of 
Ireland, which was included by the author.25 
Western Europe as a region within this 
World Bank definition includes countries of 
a similar economic background, healthcare 
provision, and geographical location. 
Furthermore, a hand search of included and 
relevant reference materials was undertaken 
to identify other sources of primary 
surveillance data for inclusion that were 
either published or in the process of being 
published. A diagram to illustrate the flow 
of information throughout this review is 
found in Figure 1. 
Box 1. Search Terms for Medline through Ovid 
Gateway 
 
Inclusion criteria 
Sources identified by the initial database 
search were exported into Mendeley 
Desktop reference management software 
Search terms for Lyme disease and Lyme 
borreliosis 
1 lyme disease/ 2 erythema migrans/ 3 erythema 
chronicum migrans/4 lyme borreliosis/5 
neuroborreliosis/6 1 or 2 or 3 or 4 or 5 
Search terms for Western European countries 
7 exp Western Europe/8 Austria/9 Belgium/10 
Denmark/11 Finland/12 France/ 13 Germany/14 
Greece/15 Iceland/16 Italy/17 Luxembourg/18 
Netherlands/19 Norway/20 Portugal/ 21 Spain/22 
Sweden/23 Switzerland/ 24 United Kingdom/25 
Scotland/26 England/27 Wales/ 28 Northern 
Ireland/29 Ireland/30 Great Britain/31 Poland/ 32 
Slovakia/33 Russia/ 34 Croatia/35 or/31-34/ 36 
or/7-30/ 37 36 not 35 / 38 37 and 6 
Search terms for epidemiological studies 
39 Epidemiologic studies/ 40 epidemiology/ 41 
epidemiology.mp./ 42 incidence/ 43 incidence.mp.  
44 or/39-43/ 45 38 and 44 
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(Version 1.1.2, 2011, Mendeley Ltd, 
London, UK) – duplicate studies were 
merged and non-human studies excluded. 
The remaining studies were then assessed 
for eligibility first by their title and abstract 
and subsequently by a more detailed review 
of the source for data regarding confirmed 
cases of LB. Where multiple reports for 
countries were available, the most recent 
data was selected. 
Papers that reported only partial sections of 
a population were excluded, unless the 
sample was representative of the entire 
population by design, so as not to bias data 
when compared with the population as a 
whole. Papers that only publish information 
on laboratory tests were not included as 
there was no way of knowing the 
demographics of the people from which the 
samples had been obtained. 
Reviews were analysed for appropriate data 
and, if found to be relevant, had their 
reference lists examined for the original 
source of data where possible. However, if 
the original source was unobtainable, then 
the review data was included. This was the 
case for data concerning Switzerland, Spain, 
and Ireland.13,26 Surveillance reports were 
included and were especially useful for more 
northern countries in providing recent 
data.5,10,27 For England and Wales, 
information was gathered from the Health 
Protection Agency, as this provided the 
most up-to-date figure of incidence.28 This 
search located 11 sources of incidence data 
for inclusion in the review, representing 17 
countries in total. No information was 
found to be available for Greece or 
Luxembourg concerning the epidemiology 
of LB. 
Data extraction 
The data extraction of incidence 
information from the included sources was 
dependent on the type of information 
provided. Most sources reported incidence 
rates per 100 000 persons per year. Belgium, 
France, and Sweden were exceptions, for 
which incidence rates were reported as the 
number of cases of erythema migrans or 
confirmed LB in general practices. Austria 
had only an estimate of LB per 100 000 
person-years based on a survey of general 
practitioners. In order to calculate the 
population-weighted averages, the mean 
population for the observation period was 
obtained from the World Bank for each 
country, with the exception of England, 
Wales, and Scotland, for which the 2011 
census data were extracted.29,30 This 
population information was also used to 
back-calculate incidence into a case 
notification rate which allowed greater 
accuracy when approximating the 
subregional burden of disease. 
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Results 
Of the sources included in this review, 3 
were surveillance reports, of which 2 were 
on a multinational level and 1 on a national 
level.5,27,31 2 reviews were also used as 
sources for data as the origins of their 
estimates were unobtainable.10,26 Incidence 
data for England and Wales was accessed 
through the Health Protection Agency, a 
governmental body.28 Data for Austria was 
obtained only through an estimate based on 
a survey of physicians in primary care, but 
has been included in previous reporting of 
Austrian incidence and, as such, was 
included in this review. The remaining 
included studies were observational studies 
undertaken at a national level that provided 
incidence rates for their relevant country. 
No data were obtained for Greece or for 
Luxembourg due to a lack of reporting in 
these countries. A summary of the initial 
extraction of results and standardized 
incidence rates are provided in Table 2. 
Countries in Western Europe have a large 
variance in the incidence rates of LB 
between both the countries themselves and 
regions within the countries. The highest 
reported incidences for LB were reported in 
southern Sweden with 464 per 100 000 and 
the lowest in Italy with only 0.001 per 
100 000.10,35 This provides a large ratio 
between these two values of 464 000:1. The 
unweighted mean for the included data 
provided an incidence of 56.3 100 000 
(median value 9.4 per 100 000, first and 
third quartiles of 1.73 and 37.4 per 100 000 
respectively), equating to an interquartile 
range of 35.57 per 100 000. As a result of 
this data, the unweighted burden of disease 
for LB in Western Europe is estimated to be 
56.3 new cases per 100 000 population per 
year, equating to approximately 232 125 
cases in one year throughout the region 
based on a total population of 412.2 million 
living in Western Europe in 2011.29,30 Using 
the total population at risk from the 
included studies or the year-specific 
population data for surveillance reports, a 
population-weighted average incidence was 
calculated. This weighted mean for the 
regional burden of LB in Western Europe is 
22.05 cases per 100 000 person-years. A 
summary of these results can be found in 
Table 1. 
 
Table 1. Summary of results 
 Statistic Value 
Mean Incidence 56.31/100 000 
Median incidence 9.4/100 000 
Maximum reported incidence 464/100 000 
Minimum reported incidence 0.001/100 000 
Max/Min ratio 464 000:1 
Range 463.999 
25th percentile 1.73/100 000 
75th percentile 37.3/100 000 
Inter-quartile range 35.57 
Weighted mean incidence 22.05/100 000 
*Incidence is expressed in person-years. 
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Table 2. Non-standardised measures, case definitions of included studies as extracted from the included studies and summary of included studies 
Reference 
 
Country/Region 
Disease 
Meaurement 
Non-Standardised 
Value (per year) 
Case Definition Study Type Study Period 
Incidence rate 
(cases/100 000/year) 
Smith et al., 20065 Austria Incidence rate 135 cases per 100 000 population 
Estimate based on a survey of 
physicians 
Surveillance 
report 
2005 135 
Vanthomme, 201232 Belgium Number of cases 338 cases of erythema migrans 
Cases reported to GPs with erythema 
migrans in Belgium 
Case reports 2008–2009 90.2 
EpiNorth, 201127 Denmark Incidence rate 1.7 cases per 100 000 population Diagnosis with Lyme borreliosis 
Surveillance 
report 
2011 1.7 
EpiNorth, 201127 Finland Incidence rate 30.92 cases per 100 000 population Diagnosis with Lyme borreliosis 
Surveillance 
report 
2011 30.92 
Letrilliat et al., 200533 France Number of cases 86 cases of Lyme borreliosis Diagnosis with Lyme borreliosis Case reports 1999–2000 9.4 
Fulop et al., 200831 Germany Incidence rate 37.3 cases per 100 000 population Diagnosis of erythema migrans 
Surveillance 
report 
2006 37.3 
No data Greece 
  
    
EpiNorth, 201127 Iceland Incidence rate 7 cases per 100 000 population Diagnosis with Lyme borreliosis 
Surveillance 
report 
2011 7 
Lindgren et al., 200610 Ireland Incidence rate 0.6 cases per 100 000 population Diagnosis with Lyme borreliosis Review 1995 0.6 
Smith et al., 20065 Italy Incidence rate 0.001 cases per 100 000 population Diagnosis with Lyme borreliosis 
Surveillance 
report 
2001–2005 0.001 
No data Luxembourg 
  
    
Hofhuis et al., 201034 Netherlands Incidence rate 
134 cases of erythema migrans per 100 000 
population 
Diagnosis of erythema migrans Case reports 2009 134 
EpiNorth, 201127 Norway Incidence rate 4.96 cases per 100 000 population Diagnosis with Lyme borreliosis 
Surveillance 
report 
2011 4.96 
Smith et al., 20065 Portugal Incidence rate 0.04 cases per 100 000 population Diagnosis with Lyme borreliosis 
Surveillance 
report 
2005 0.04 
Lindgren et al., 200610 Spain (La Rioja) Incidence rate 9.8 cases per 100 000 population Diagnosis with Lyme borreliosis Review 2003 9.8 
Bennet et al., 200635 Sweden Incidence rate 
Annual mean incidence of 464 cases of 
erythema migrans per 100 000 population 
Cases reported with erythema 
migrans in Blekinge County 
Case reports 1997–2002 464 
Hubalek et al., 200926 Switzerland Incidence rate 25.1 cases per 100 000 population Diagnosis with Lyme borreliosis Review 1988–1998 25.1 
Health Protection Agency, 201128 
United Kingdom 
(England & Wales) 
Incidence rate 1.7 cases per 100 000 population Diagnosis with Lyme borreliosis 
Government 
figures 
2011 1.73 
Slack et al., 201112 
United Kingdom 
(Scotland) 
Incidence rate  5.53 cases per 100 000 population Diagnosis with Lyme borreliosis  
Surveillance 
study  
2009–2010 5.53 
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Discussion 
A large level of heterogeneity was found to 
be present throughout the incidence data for 
LB in Western Europe. The reasons for this 
include different case definitions, collecting 
methods, and that very few countries 
include LB as a compulsorily notifiable 
disease. Overdiagnosis and underdiagnosis 
of LB is another important factor with a 
significant impact on the number of 
reported cases. In other countries, it is 
suggested that the general public are simply 
not aware of the risk of LB and as such 
neglect symptoms, especially if erythema 
migrans does not develop.10 However, with 
such limitations in mind, the estimates 
provided by this study will give at very least 
a minimum illustration of the burden of 
disease in Western Europe, which 
demonstrates the importance of LB as a 
continually emerging infection to healthcare 
authorities and governments throughout the 
region. This will hopefully encourage a more 
standardized approach to data collection. 
When compared with previous studies, 
these most recently available data indicate 
that the incidence of LB in certain European 
countries may be increasing faster than 
expected by population growth alone. Such 
increases have been observed in Germany, 
the Netherlands, and the United Kingdom, 
among others.31,34,36 These increases may 
simply be due to an improvement in 
reporting practices, raised awareness of the 
disease, or overdiagnosis of LB. However, 
tick numbers and activity are closely 
associated with the number of cases of LB 
and an amplification of these reported by 
other studies cannot be ignored.37,38 Ticks, 
similarly to other arthropods, are sensitive to 
changes in climate as most of their life cycle 
is dependent on climatic variables, especially 
development and survival.39 A smaller factor 
is that of vegetation levels and host 
availability – as humans venture into the 
greener areas of a country either for work or 
recreation, the likelihood of them becoming 
a host inevitably increases.40,41 The 
increasing number of ticks has been 
hypothesized to be associated with the 
warming of the climate as the ideal 
conditions for ticks are amongst vegetation 
that maintains a high level of humidity.41 
One review has provided a theoretical 
projection of the effect that climate change 
will have on the burden of disease attributed 
to LB, predicting that LB will continue to 
spread into higher latitudes and altitudes, 
will have an extended and more intense 
transmission season in certain areas of 
Europe, and that the risk of LB may 
decrease in areas where there are repeated 
droughts or severe floods.10 
Another factor influencing the observed 
heterogeneity of results, as displayed by the 
large maximum to minimum range and 
interquartile range of the included data, 
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could be differences in population 
structures. While all individuals who expose 
themselves to the environment in which 
these arthropods thrive will be at risk, 
differences in urban and rural populations 
between countries would therefore have an 
effect on the risk of being infected with LB. 
This could work in either direction as, 
although rural workers and populations are 
at increased risk from their local 
environment, urban dwellers tend to have a 
decreased awareness which increases the risk 
of being infected and not recognizing the 
disease.42 Some studies have also identified 
differences in the age groups of those 
affected. While some studies have found 
that children and older people are more 
often affected by LB, others note the 
opposite with predominantly adult working 
age groups affected.12,31 This demonstrates 
that there are likely to be differences in 
exposure risk for age groups between 
countries and, as such, both geographical 
and population demographics may influence 
incidence, although the direct mechanism 
remains unclear. 
Although data for the majority of countries 
were obtainable, there are clear information 
gaps created by lacking or absent disease 
reporting, such as in Greece and 
Luxembourg. The countries reporting very 
low incidences such as Italy are likely 
underestimated, as studies exist 
demonstrating the existence of Borrelia 
burgdorferi in these countries and the 
presence of at-risk areas.43 These gaps in 
data could be improved by a region-wide 
initiative towards improved reporting of LB 
as a notifiable disease. However, there 
currently seems to be little progress in this 
area, which should be reviewed both for 
disease burden and the financial burden on 
European health systems, which is estimated 
to be over €1000 million.5,42,44 
A suggestion for future research into LB in 
Western Europe is continued 
epidemiological surveillance as well as 
investigation into the disease status in 
countries for which there is little or no data. 
In countries where different areas vary 
greatly in incidence, it would be of interest 
to continue surveillance within different 
regions, as it is sensible to expect that areas 
with different tick densities will have 
different incidence rates. This is important 
in countries where only one region is 
reported, such as in Spain, as it is likely that 
these smaller reported areas are not 
representative of the whole country. Where 
studies are designed on a smaller scale, it is 
important to focus on a unified approach to 
case definition, and an example of a 
consensus case definition has been 
published.45 Variation on the definition of a 
case of LB across the included sources is 
evident in this review. LB is a diagnosis 
made on a combination of clinical signs and 
symptoms as well as appropriate laboratory 
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testing. Serology testing alone should not be 
encouraged because this in itself is not 
diagnostic. Conversely, while erythema 
migrans is a diagnostic finding for LB, it is 
not present in up to 30% of cases. There are 
complexities surrounding definitive criteria 
for diagnosis due to current variations 
between countries; however, a region-wide 
case definition used in reporting may help to 
improve the accuracy and reporting of LB 
diagnoses. Further research into 
preventative measures aiming to minimize 
the risk of being bitten by a tick should also 
be conducted, as this is the only certain way 
to avoid being infected. 
Conclusions 
LB is a continually emerging disease and the 
most common zoonotic infection in 
Western Europe, approaching endemic 
proportions in many European countries. 
The population-weighted incidence has been 
estimated by this study to be 22.04 per 
100 000 person-years. This review 
encourages further establishment of well-
conducted and concordant surveillance 
research in order to monitor the disease in 
the ever-changing climate where tick 
numbers and activity are increasing, leading 
to greater risks of infection. 
 
 
 
  
Learning Points 
 What is already known 
 Lyme borreliosis is an important disease with wide-ranging health and economic 
impacts and a substantial global health burden. 
 It is the most common zoonotic infection in Western Europe. 
 Incidence of LB is increasing and little is being done to address this increase. 
 Increase in tick numbers may be partly due to climate change. 
What this article adds 
 This study estimates the population-weighted incidence of Lyme borreliosis in Western 
Europe to be 22.04 per 100 000 person-years. 
 There is no unified approach to surveillance or diagnostic criteria for the disease. 
 Further evidence that Lyme borreliosis is established within Western Europe and that 
it is an important topic that requires further research and investment from governing 
bodies. 
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